Cann Group Ltd. · ASX:CAN
Cann — Investor Presentation (March 2019)
20 slides from Cann's investor presentation, Mar 21, 2019
Slide 1: Investor presentation
GROUP LIMITED Investor presentation March 2019 1 Shining light on medicinal cannabis
Slide 2: Disclaimer
Disclaimer This investor presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 Future performance 949 739) (Cann) and comprises written material regarding Cann. This Presentation contains certain ‘forward looking statements’, including but not limited to projections, guidan
Slide 3: Disclaimer
Disclaimer Affiliates All rights reserved None of Cann’s respective advisers or any of their respective affiliates, related bodies corporate, directors, Several photographs contained in this Presentation are the property of Cann and are protected officers, partners, employees and agents, have author
Slide 4: Mission
Mission Supply high-quality, trusted & innovative medicinal cannabis products & delivery platforms to enhance the wellbeing of patients in Australia & globally. 4 Shining light on medicinal cannabis
Slide 5: Cann Group is an industry leader in Australia
Cann Group is an industry leader in Australia • First Australian recipient of research & medicinal cannabis cultivation licences & permits • Two cultivation & R&D facilities currently operational in Victoria • Site secured for major Stage 3 expansion near Mildura, Victoria – works to commence immedi
Slide 6: Major expansion plans comprising world class facility
Major expansion plans comprising world class facility • Mildura site to be purchased for $10.75m • State-of-the-art 34,000m² facility comprising world scale greenhouse & associated support areas • Expected production capacity of 50,000 kg of dry flower per annum • Facility to be fully commissioned i
Slide 7: Offtake agreement with strategic investor Aurora Cannabis Inc.
Offtake agreement with strategic investor Aurora Cannabis Inc. •Five-year offtake agreement underpins Cann’s investment risk in its major expansion program •Covers Cann’s total current & planned future capacity (subject to satisfaction of Australian demand) •Cann to supply GMP processed dry flower,
Slide 8: Mildura facility provides a clear pathway to sustained profitability
Mildura facility provides a clear pathway to sustained profitability Specialised components/ Design & materials engineering delivered Operating completed at full Stage 1 capacity Site works Greenhouse, Mother room GACP/GMP begin irrigation and table commissioning Packaging systems installations Stag
Slide 9: Manufacturing partnership with IDT Australia
Manufacturing partnership with IDT Australia • IDT Australia (ASX:IDT) to provide manufacturing support in relation to cannabis-based product formulations • Intended for supply to patients in Australia & overseas • IDT brings excellent capabilities & experience in the manufacture of cGMP quality pha
Slide 10: Proven capability with continuous cultivation since May 2017
Proven capability with continuous cultivation since May 2017 • Most experienced cultivator in Australia • 36 crops now harvested • Southern & Northern facilities provide important springboard for large scale cultivation • Mildura will be Cann’s third facility • Ongoing supply with Victorian Departme
Slide 11: Existing facilities add critical long term value
Existing facilities add critical long term value Southern Facility Northern Facility • Proven capability to produce medicinal grade cannabis • Combining commercial & research cultivation • Continues to operate at full-capacity capabilities • Harvested material is being supplied for manufacture • Foc
Slide 12: Supply agreement with Victorian DHHS
Supply agreement with Victorian DHHS • Contract with Victorian DHHS for the supply of cannabis plant extract (resin) • For use in Victorian Government’s compassionate access scheme for children with severe & intractable epilepsy • Agreement term – April 2019-30 June 2020 • Revenue stream for Cann –
Slide 13: Key partnerships complement in-house skills & capabilities
Key partnerships complement in-house skills & capabilities • New research collaboration agreement signed with CSIRO • Research program underway with Agriculture Victoria • Cann Group is the key commercial partner in the Australian Research Council funded La Trobe University Medicinal Agriculture Hub
Slide 14: Substantial & rapidly growing global market
Substantial & rapidly growing global market • Estimated global legal market – US$20 billion¹ (~US$232 billion projected by 2027²) • More than 50 countries have legalised medicinal cannabis – momentum continues with another ~10 expected this year³ • Recreational use in markets such as Canada placing
Slide 15: Local & export opportunities
Local & export opportunities Australian market Export opportunity • Access legalised in 2017, state hurdles being • 342,103 registered patients² + recreational removed use in Canada (forecast demand 650,000kg³) means shortage it has available for export • Special Access Scheme allowing patient presc
Slide 16: Blue-chip board & management with extensive, broad experience
Blue-chip board & management with extensive, broad experience • Allan has extensive experience in the agribusiness • Experienced public company director sector as well as significant tenures with biotechnology • Co-founded Premier Artists & Frontier Touring Company companies • Very strong financial
Slide 17: Exciting growth opportunity for Cann Group
Exciting growth opportunity for Cann Group • Building the capability & strength of the management team • Cann continues to grow the team with opportunities available for people with horticultural, pharmaceutical, manufacturing & engineering experience • Working collaboratively on a focused growth st
Slide 18: Corporate structure
Corporate structure METRIC VALUE (20/3/19) Share price $2.01 Shares on issue (fully diluted) 142.65m Market capitalisation $286.73m Cash $72.6m (31/12/18) Enterprise value $214.13m 18 Shining light on medicinal cannabis
Slide 19: Outlook
Outlook Newsflow over the next several months includes: • Supply of resin to Victorian Department of Health • IDT manufacturing (pending regulatory approval) • Clinical study involvement • Focus on Australian patient supply • Testing of export pathways with Aurora • Progress Mildura facility 19 Shin
Slide 20: Contacts
GROUP LIMITED CONTACTS: Peter Crock CEO Cann Group Limited +61 (0)3 9095 7088 contact@canngrouplimited.com INVESTOR / MEDIA RELATIONS Matthew Wright NWR Communications +61 (0)451 896 420 matt@nwrcommunications.com.au 20 Shining light on medicinal cannabis